NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Price, News & Analysis $1.35 -0.02 (-1.10%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$1.34▼$1.3950-Day Range$1.19▼$1.5052-Week Range$0.99▼$1.89Volume18,993 shsAverage Volume214,720 shsMarket Capitalization$72.89 millionP/E Ratio3.14Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Spero Therapeutics alerts: Email Address Spero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside430.3% Upside$7.00 Price TargetShort InterestHealthy0.66% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$42,646 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.59) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.65 out of 5 starsMedical Sector62nd out of 924 stocksPharmaceutical Preparations Industry21st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Spero Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.66% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 8.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Spero Therapeutics is -0.80. Previous Next 1.1 News and Social Media Coverage Search Interest1 people have searched for SPRO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,646.00 in company stock.Percentage Held by InsidersOnly 4.52% of the stock of Spero Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.60% of the stock of Spero Therapeutics is held by institutions.Read more about Spero Therapeutics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($1.59) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 3.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 3.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.67.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Spero Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchFamous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.To watch his fascinating interview which has taken Wall Street by storm, click here. About Spero Therapeutics Stock (NASDAQ:SPRO)Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More SPRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRO Stock News HeadlinesAugust 8, 2024 | insidertrades.comSath Shukla Sells 17,641 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) StockAugust 7, 2024 | insidertrades.comSath Shukla Sells 14,800 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) StockAugust 22, 2024 | Porter & Company (Ad)This technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.August 10, 2024 | ca.investing.comEarnings call: Spero Therapeutics Q2 2024 update highlights pipeline progressAugust 9, 2024 | seekingalpha.comSpero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | uk.finance.yahoo.comIndia's Marico says majority of retail distributors resume ops in BangladeshAugust 8, 2024 | finance.yahoo.comSpero Therapeutics Second Quarter 2024 Earnings: Beats ExpectationsAugust 7, 2024 | msn.comTD Cowen Upgrades Spero Therapeutics (SPRO)August 22, 2024 | Porter & Company (Ad)This technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.August 6, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business UpdateAugust 6, 2024 | markets.businessinsider.comBuy Rating Affirmed on Spero Therapeutics as Drug Pipeline ProgressesAugust 5, 2024 | globenewswire.comSpero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business UpdateJuly 29, 2024 | globenewswire.comSpero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024July 8, 2024 | investorplace.com3 Micro-Cap Moonshots for Fearless InvestorsJuly 3, 2024 | globenewswire.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | globenewswire.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business UpdateMay 16, 2024 | globenewswire.comSpero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor ConferenceSee More Headlines Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRO CUSIPN/A CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees150Year Founded2013Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+430.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.43 Trailing P/E Ratio3.07 Forward P/E RatioN/A P/E GrowthN/ANet Income$22.81 million Net Margins14.74% Pretax Margin16.93% Return on Equity25.67% Return on Assets14.26% Debt Debt-to-Equity RatioN/A Current Ratio2.68 Quick Ratio2.68 Sales & Book Value Annual Sales$103.78 million Price / Sales0.69 Cash Flow$0.57 per share Price / Cash Flow2.30 Book Value$2.02 per share Price / Book0.65Miscellaneous Outstanding Shares53,990,000Free Float51,547,000Market Cap$71.27 million OptionableOptionable Beta0.63 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Ankit Mahadevia M.D. (Age 43)MBA, Co-Founder & Chairman of the Board Comp: $1.39MMr. Satyavrat Shukla C.F.A. (Age 51)President, CEO & Director Comp: $1.12MMr. Timothy Keutzer (Age 56)Chief Operating Officer Comp: $938.57kMs. Esther P. Rajavelu (Age 45)CFO, Chief Business Officer & Treasurer Mr. James P. BradyChief Human Resource OfficerDr. Kamal Hamed M.B.A. (Age 63)M.D., M.P.H., Chief Medical Officer More ExecutivesKey CompetitorsAeglea BioTherapeuticsNASDAQ:AGLETetraphase PharmaceuticalsNASDAQ:TTPHPoseida TherapeuticsNASDAQ:PSTXEnanta PharmaceuticalsNASDAQ:ENTAAmarinNASDAQ:AMRNView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 121,492 shares on 8/9/2024Ownership: 1.808%Atlas Venture Life Science Advisors LLCSold 72,277 shares on 8/9/2024Ownership: 0.992%Acadian Asset Management LLCBought 309,262 shares on 8/6/2024Ownership: 1.985%Sath ShuklaSold 17,641 sharesTotal: $23,109.71 ($1.31/share)Sath ShuklaSold 14,800 sharesTotal: $19,536.00 ($1.32/share)View All Insider TransactionsView All Institutional Transactions SPRO Stock Analysis - Frequently Asked Questions How have SPRO shares performed this year? Spero Therapeutics' stock was trading at $1.47 at the beginning of the year. Since then, SPRO stock has decreased by 10.2% and is now trading at $1.32. View the best growth stocks for 2024 here. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings results on Monday, August, 5th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company had revenue of $10.20 million for the quarter, compared to analysts' expectations of $9.80 million. Spero Therapeutics had a net margin of 14.74% and a trailing twelve-month return on equity of 25.67%. What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO? 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Spero Therapeutics IPO? Spero Therapeutics (SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Spero Therapeutics' major shareholders? Top institutional shareholders of Spero Therapeutics include Acadian Asset Management LLC (1.99%), Renaissance Technologies LLC (1.81%) and Atlas Venture Life Science Advisors LLC (0.99%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:SPRO) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
